Evotec SE ended 2020 with liquidity of €481.9 million and a portfolio of co-owned research assets, equity investments and clinical-stage pharma projects underpinning its work as a global drug discovery company. Revenue for the year was €500.9 million, up by 12% from 2019. Operating profit was €48.5 million, down by 22% due to delayed milestone payments and higher investments in R&D.
At a briefing for analysts on 25 March, Werner Lanthaler, the chief executive, said the financial outlook is strong for the current year. He also outlined a new strategy for the period up to 2025.